Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.

Huang H, Guzman-Perez A, Acquaviva L, Berry V, Bregman H, Dovey J, Gunaydin H, Huang X, Huang L, Saffran D, Serafino R, Schneider S, Wilson C, DiMauro EF.

ACS Med Chem Lett. 2013 Oct 21;4(12):1218-23. doi: 10.1021/ml4003315. eCollection 2013 Dec 12.

2.

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

Hua Z, Bregman H, Buchanan JL, Chakka N, Guzman-Perez A, Gunaydin H, Huang X, Gu Y, Berry V, Liu J, Teffera Y, Huang L, Egge B, Emkey R, Mullady EL, Schneider S, Andrews PS, Acquaviva L, Dovey J, Mishra A, Newcomb J, Saffran D, Serafino R, Strathdee CA, Turci SM, Stanton M, Wilson C, Dimauro EF.

J Med Chem. 2013 Dec 27;56(24):10003-15. doi: 10.1021/jm401317z. Epub 2013 Dec 11.

PMID:
24294969
3.

AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.

Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R.

Mol Cancer Ther. 2013 Nov;12(11):2356-66. doi: 10.1158/1535-7163.MCT-12-1178. Epub 2013 Aug 29.

4.

Structure-Based Design of Potent and Selective CK1γ Inhibitors.

Huang H, Acquaviva L, Berry V, Bregman H, Chakka N, O'Connor A, DiMauro EF, Dovey J, Epstein O, Grubinska B, Goldstein J, Gunaydin H, Hua Z, Huang X, Huang L, Human J, Long A, Newcomb J, Patel VF, Saffran D, Serafino R, Schneider S, Strathdee C, Tang J, Turci S, White R, Yu V, Zhao H, Wilson C, Martin MW.

ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64. doi: 10.1021/ml300278f. eCollection 2012 Dec 13.

5.

Impact of hydrolysis-mediated clearance on the pharmacokinetics of novel anaplastic lymphoma kinase inhibitors.

Teffera Y, Berry LM, Brake RL, Lewis RT, Saffran DC, Moore E, Liu J, Zhao Z.

Drug Metab Dispos. 2013 Jan;41(1):238-47. doi: 10.1124/dmd.112.047993. Epub 2012 Nov 1.

PMID:
23118327
6.

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.

Coxon A, Ziegler B, Kaufman S, Xu M, Wang H, Weishuhn D, Schmidt J, Sweet H, Starnes C, Saffran D, Polverino A.

Mol Cancer. 2012 Sep 19;11:70. doi: 10.1186/1476-4598-11-70.

7.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL.

J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10.

PMID:
22734674
8.

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. 1993.

Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, Belmont JW, Cooper MD, Conley ME, Witte ON.

J Immunol. 2012 Apr 1;188(7):2936-47. No abstract available.

9.

Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.

Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.

Clin Cancer Res. 2009 Jan 1;15(1):110-8. doi: 10.1158/1078-0432.CCR-08-1155.

10.

Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.

Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E, Saffran DC, Raitano AB, Jakobovits A.

Cancer Res. 2001 Feb 15;61(4):1686-92.

11.

Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.

Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2658-63. Epub 2001 Feb 13.

12.

Target antigens for prostate cancer immunotherapy.

Saffran DC, Reiter RE, Jakobovits A, Witte ON.

Cancer Metastasis Rev. 1999;18(4):437-49. Review.

PMID:
10855787
13.

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.

Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE.

Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523-8.

14.

Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.

Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE.

Cancer Gene Ther. 1998 Sep-Oct;5(5):321-30.

PMID:
9824052
15.

Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection.

Walsh CM, Hayashi F, Saffran DC, Ju ST, Berke G, Clark WR.

J Immunol. 1996 Feb 15;156(4):1436-41.

PMID:
8568245
16.

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.

Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON.

Cell. 1995 Sep 22;82(6):981-8.

17.

Development of btk transgenic mice.

Faust EA, Rawlings DJ, Saffran DC, Witte ON.

Curr Top Microbiol Immunol. 1995;194:363-70. No abstract available.

PMID:
7895510
18.

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).

Zhu Q, Zhang M, Rawlings DJ, Vihinen M, Hagemann T, Saffran DC, Kwan SP, Nilsson L, Smith CI, Witte ON, Chen SH, Ochs HD.

J Exp Med. 1994 Aug 1;180(2):461-70.

19.

Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.

Saffran DC, Parolini O, Fitch-Hilgenberg ME, Rawlings DJ, Afar DE, Witte ON, Conley ME.

N Engl J Med. 1994 May 26;330(21):1488-91. No abstract available.

20.

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.

Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, Mohr RN, Bazan JF, Howard M, Copeland NG, et al.

Science. 1993 Jul 16;261(5119):358-61.

PMID:
8332901
21.

Distinctive growth requirements and gene expression patterns distinguish progenitor B cells from pre-B cells.

Faust EA, Saffran DC, Toksoz D, Williams DA, Witte ON.

J Exp Med. 1993 Apr 1;177(4):915-23.

22.

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, et al.

Cell. 1993 Jan 29;72(2):279-90.

PMID:
8425221
23.

Establishment of a reproducible culture technique for the selective growth of B-cell progenitors.

Saffran DC, Faust EA, Witte ON.

Curr Top Microbiol Immunol. 1992;182:37-43. No abstract available.

PMID:
1490376
25.
27.

Identification of a human bone marrow-derived immunoenhancing factor, BDEF.

Mortari F, Saffran DC, Singhal SK.

Cell Immunol. 1989 Jun;121(1):154-65.

PMID:
2655932
28.

Supplemental Content

Loading ...
Support Center